Comparative epitope mapping of sera from United States (US) and Japanese patients with bullous pemphigoid (BP) to fusion proteins encoded by BPAG1

Journal of Dermatological Science

Volumn 12, Issue 3, 1996, Pages 238-245

  Rico, M Joyce ^a   Hashimototo, Takashi ^b   Watanabe, Kyoko ^b   Hall, Russell P ^c   Clark, Rachel B ^c   Nishikawa, Takeji ^b  

^a NEW YORK UNIVERSITY   (United States)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; B cell epitope; Bullous pemphigoid; ELISA; Fusion protein

Indexed keywords

HYBRID PROTEIN;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PEMPHIGOID; PRIORITY JOURNAL;

EID: 0030248192     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/0923-1811(95)00479-3     Document Type: Article

References (13)

1. [1] Hashimoto T, Ebihara T, Ishiko A et al.: Comparative study of bullous pemphigoid antigens among Japanese, British, and US patients indicates similar antigen profiles with the 170-kD antigen present both in the basement membrane and on the keratinocyte cell membrane. J Invest Dermatol 100: 385-389, 1993.
2. [2] Miller JE, Rico MJ, Hall RP: IgG in the serum of patients with bullous pemphigoid binds to fusion proteins encoded by BPAg1 cDNA. J Invest Dermatol 101: 779-782, 1993.
3. [3] Sugi T, Hashimoto T, Hibi T, Nishikawa T: Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. J Clin Invest 84: 1050-1055, 1989.
4. [4] Giudice GJ, Wilske K, Anhalt GJ et al.: Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol 102: 878-881, 1994.
5. [5] Stanley JR, Tanaka T, Mueller S et al.: Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 82: 1864-1870, 1988.
6. [6] Tanaka M, Hashimoto T, Amagai M et al.: Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins. J Invest Dermatol 97: 725-728, 1991.
7. [7] Cunningham MW, Antone SN4, Gulizia JM et al.: α-Helical coiled-coil molecules: A role in autoimmunity against the heart. Clin Immunol Immunopathol 68: 118-123, 1993.
8. [8] Ahmed AR, Konqui A, Park MA et al.: HLA antigens in bullous pemphigoid. Arch Dermatol 120: 795, 1984.
9. [9] Schaller J, Feleke W, Haustein UF et al.: HLA in bullous pemphigoid: The probable role of HLA-B7 as a marker for poor responders to immunosuppressive therapy. Int J Dermatol 30: 36-38, 1991.
10. [10] Venning VA, Wojnarowska F: The association of bullous pemphigoid and malignant disease: A case control study. Br J Dermatol 123: 439-445, 1990.
11. [11] Hashimoto K, Miki Y, Nakata S et al.: HLA-A10 in pemphigus among Japanese. Arch Dermatol 115: 96-97, 1977.
12. [12] Saitta MR, Arnett FC, Keene JD: 60-kDa Ro protein autoepitopes identified using recombinant polypeptides. J Immunol 152: 4192-4202, 1994.
13. [13] Amagai M, Hashimoto T, Shimizu N, Nishikawa T: Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 94: 59-67, 1994.